Filing Flows › Health Care › Novartis AG (NVS)
Novartis AG (NVS) earnings and revenue breakdown
Latest: Q3 2026 · 6-K filed Oct 27, 2026 · Novartis AG (NVS) Q3 2026 earnings results →
Q3 2026 Revenue up 4% year over year to $14.5B · 8¢ of every $1 of revenue kept as net profit · operating margin 12.7%
Novartis AG made $14.5B in Q3 2026 (+4% Y/Y). Operating margin 12.7%, net earnings $1.2B. See where every dollar goes — costs, profit and cash — as a Sankey from the 6-K filed Oct 27, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $14.5B in Q3 2026, up 4% year over year.
Operating profit was $1.8B, a 12.7% margin (down 19.7 points year over year). Operating profit fell $2.7B even though revenue rose $0.61B versus a year earlier, so costs grew faster than sales. Total costs grew 35% against revenue growth of 4%. Net earnings were $1.2B, down 70% year over year. The effective tax rate was 0.0%.
Operating cash flow was $5.5B (down 16% year over year), 460% of net earnings. Working capital and other items added $4.3B.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 6-K | Oct 27, 2026 | $14.5B | +4% | 12.7% | $1.2B | $5.5B |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About Novartis AG
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn , Facebook , X/Twitter and Instagram .
In its own words, from its 6-K, filed Oct 27, 2026.
Novartis AG against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +4% against the peers' median +6%. Operating margin: 12.7% against the peers' median 30.1%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| NVS Novartis AG | Q3 2026 | $14.5B | +4% | 12.7% |
| NVO Novo Nordisk A S | FY2025 | $46.8B | +6% | 41.3% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| SNY Sanofi | Q3 2026 | $16.6B | +16% | 30.1% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
Source: Novartis AG 6-K on SEC EDGAR · CIK 1114448 · Pharmaceutical Preparations
13F: who owns NVS and who is buying
More on NVS
History
Every quarter: Q3 2026 results